Dr. Sankhala on the TRC105/Pazopanib Combination in Angiosarcoma

Video

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

Pazopanib is approved for the treatment of advanced angiosarcoma, but evidence of activity has been modest, with a median progression-free survival (PFS) of 3 months, and a median overall survival (OS) of 9.9 months, according to a recent study in which none of the patients achieved complete responses.

Endoglin is a surface receptor expressed on activated endothelium, including tumor vasculature, and it is also expressed on angiosarcoma tumor tissue and could be a potential driver of this endothelial malignancy. The receptor may mediate resistance to pazopanib. A phase Ib/IIa study of the endoglin antibody TRC105 combined with pazopanib in patients with advanced soft tissue sarcoma was previously reported at the 2016 ASCO meeting. The current results demonstrate this combination’s activity in an expansion cohort of patients with angiosarcoma.

In this expansion cohort, the combination treatment was both active and well tolerated, and it led to durable complete responses. A global phase III study of pazopanib with or without TRC105 is now planned.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD